Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Change in Acquisitions & Divestments (2017 - 2025)

Historic Change in Acquisitions & Divestments for Lisata Therapeutics (LSTA) over the last 9 years, with Q3 2025 value amounting to $5.1 million.

  • Lisata Therapeutics' Change in Acquisitions & Divestments fell 4379.57% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 million, marking a year-over-year decrease of 4754.76%. This contributed to the annual value of $69.1 million for FY2024, which is 3640.6% down from last year.
  • Latest data reveals that Lisata Therapeutics reported Change in Acquisitions & Divestments of $5.1 million as of Q3 2025, which was down 4379.57% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, Lisata Therapeutics' Change in Acquisitions & Divestments registered a high of $34.4 million during Q1 2023, and its lowest value of $4.6 million during Q2 2025.
  • Over the past 3 years, Lisata Therapeutics' median Change in Acquisitions & Divestments value was $15.4 million (recorded in 2023), while the average stood at $18.4 million.
  • As far as peak fluctuations go, Lisata Therapeutics' Change in Acquisitions & Divestments tumbled by 1483.45% in 2024, and later tumbled by 7836.85% in 2025.
  • Over the past 3 years, Lisata Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $15.4 million in 2023, then decreased by 14.83% to $13.1 million in 2024, then plummeted by 60.76% to $5.1 million in 2025.
  • Its last three reported values are $5.1 million in Q3 2025, $4.6 million for Q2 2025, and $14.5 million during Q1 2025.